In Brief: Immunomedics
This article was originally published in The Gray Sheet
Executive Summary
Immunomedics: Initiates Phase III clinical trials for LymphoScan, a nuclear imaging product for the detection of lymphoma, the firm announces July 24. The trials, which will involve approximately 250 patients at over 20 U.S. and European sites, will determine the device's ability to detect the presence, location and extent of non-Hodgkin's lymphomas, and its capability to distinguish residual disease from non-malignant fibrosis in patients undergoing drug or radiation therapy. In Phase II trials, LymphoScan demonstrated 86% sensitivity for lymphoma detection and 100% positive predictive rate for the presence of disease in 43 patients, the Morris Plains, New Jersey firm claims...